Udo Holtick1,2, Jens-Markus Chemnitz1, Alexander Shimabukuro-Vornhagen1,2, Sebastian Theurich1,2, Geothy Chakupurakal1,2, Anke Krause1, Anne Fiedler2, Leo Luznik3, Martin Hellmich4, Dominik Wolf5, Michael Hallek1, Michael von Bergwelt-Baildon1,2, Christof Scheid1. 1. Stem Cell Transplantation Program, Department I of Internal Medicine, Center for Integrated Oncology CIO KölnBonn, University Hospital of Cologne, Cologne, Germany. 2. Cologne Interventional Immunology, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. 3. Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany. 5. Medical Clinic III for Oncology, Haematology and Rheumatology, Center for Integrated Oncology CIO KölnBonn, University Hospital Bonn, Bonn, Germany.
Abstract
OBJECTIVE: Post-transplant cyclophosphamide is increasingly used as graft-versus-host disease (GvHD) prophylaxis in the setting of bone marrow transplantation. No data have been published on the use of single-agent GvHD prophylaxis with post-transplant cyclophosphamide in the setting of peripheral blood stem cell transplantation (PBSCT). METHODS: In a phase II trial, 11 patients with myeloma or lymphoma underwent conditioning with fludarabine and busulfan followed by T-replete PBSCT and application of 50 mg/kg/d of cyclophosphamide on day+3 and +4 without other concurrent immunosuppression (IS). RESULTS: Median time to leukocyte, neutrophil, and platelet engraftment was 18, 21, and 18 d. The incidence of grade II-IV and grade III-IV GvHD was 45% and 27%, with a non-relapse mortality (NRM) of 36% at one and 2 yr. After median follow-up of 927 d, overall and relapse-free survival was 64% and 34%. Three patients did not require any further systemic IS until day+100 and thereafter. Analysis of immune reconstitution demonstrated rapid T- and NK-cell recovery. B- and CD3+/CD161+NK/T-cell recovery was superior in patients not receiving additional IS. CONCLUSION: Post-transplant cyclophosphamide as sole IS in PBSCT is feasible and allows rapid immune recovery. Increased rates of severe acute GvHD explain the observed NRM and may advise a temporary combination partner such as mTor-inhibitors in the PBSCT setting.
OBJECTIVE:Post-transplant cyclophosphamide is increasingly used as graft-versus-host disease (GvHD) prophylaxis in the setting of bone marrow transplantation. No data have been published on the use of single-agent GvHD prophylaxis with post-transplant cyclophosphamide in the setting of peripheral blood stem cell transplantation (PBSCT). METHODS: In a phase II trial, 11 patients with myeloma or lymphoma underwent conditioning with fludarabine and busulfan followed by T-replete PBSCT and application of 50 mg/kg/d of cyclophosphamide on day+3 and +4 without other concurrent immunosuppression (IS). RESULTS: Median time to leukocyte, neutrophil, and platelet engraftment was 18, 21, and 18 d. The incidence of grade II-IV and grade III-IV GvHD was 45% and 27%, with a non-relapse mortality (NRM) of 36% at one and 2 yr. After median follow-up of 927 d, overall and relapse-free survival was 64% and 34%. Three patients did not require any further systemic IS until day+100 and thereafter. Analysis of immune reconstitution demonstrated rapid T- and NK-cell recovery. B- and CD3+/CD161+NK/T-cell recovery was superior in patients not receiving additional IS. CONCLUSION:Post-transplant cyclophosphamide as sole IS in PBSCT is feasible and allows rapid immune recovery. Increased rates of severe acute GvHD explain the observed NRM and may advise a temporary combination partner such as mTor-inhibitors in the PBSCT setting.
Authors: Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs Journal: Blood Date: 2010-02-02 Impact factor: 22.113
Authors: Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon Journal: J Clin Oncol Date: 2013-02-19 Impact factor: 44.544
Authors: Philippe Armand; Haesook T Kim; Vincent T Ho; Corey S Cutler; John Koreth; Joseph H Antin; Ann S LaCasce; Eric D Jacobsen; David C Fisher; Jennifer R Brown; George P Canellos; Arnold S Freedman; Robert J Soiffer; Edwin P Alyea Journal: Biol Blood Marrow Transplant Date: 2008-04 Impact factor: 5.742
Authors: Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer Journal: N Engl J Med Date: 2012-10-18 Impact factor: 91.245
Authors: Orly R Klein; Allen R Chen; Christopher Gamper; David Loeb; Elias Zambidis; Nicolas Llosa; Jeffrey Huo; Amy E Dezern; Diana Steppan; Nancy Robey; Mary Jo Holuba; Kenneth R Cooke; Heather J Symons Journal: Biol Blood Marrow Transplant Date: 2016-02-06 Impact factor: 5.742
Authors: Christopher G Kanakry; Javier Bolaños-Meade; Yvette L Kasamon; Marianna Zahurak; Nadira Durakovic; Terry Furlong; Marco Mielcarek; Marta Medeot; Ivana Gojo; B Douglas Smith; Jennifer A Kanakry; Ivan M Borrello; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; William H Matsui; Lode J Swinnen; Kenneth R Cooke; Richard F Ambinder; Ephraim J Fuchs; Marcos J de Lima; Borje S Andersson; Ravi Varadhan; Paul V O'Donnell; Richard J Jones; Leo Luznik Journal: Blood Date: 2017-01-03 Impact factor: 22.113
Authors: Mi Kwon; Rebeca Bailén; María Jesús Pascual-Cascón; Ana Isabel Gallardo-Morillo; Abel García Sola; Pascual Balsalobre; Laura Solán; Nieves Dorado; Cristina Muñoz; David Serrano; Carolina Martínez-Laperche; Ismael Buño; Javier Anguita; José Luis Díez-Martin Journal: Blood Adv Date: 2019-11-12
Authors: Elad Jacoby; Allen Chen; David M Loeb; Christopher J Gamper; Elias Zambidis; Nicolas J Llosa; Jeffrey Huo; Kenneth R Cooke; Rick Jones; Ephraim Fuchs; Leo Luznik; Heather J Symons Journal: Biol Blood Marrow Transplant Date: 2015-09-04 Impact factor: 5.742
Authors: Rebeca Bailén; Mi Kwon; María Jesús Pascual-Cascón; Christelle Ferrà; Jaime Sanz; Anabel Gallardo-Morillo; Abel García-Sola; Anna Torrent; María José Jiménez-Lorenzo; José Luis Piñana; Juan Montoro; Gillen Oarbeascoa; Nieves Dorado; Ignacio Gómez-Centurión; Cristina Muñoz; Carolina Martínez-Laperche; Javier Anguita; Ismael Buño; José Luis Díez-Martín Journal: Ann Hematol Date: 2020-11-02 Impact factor: 3.673